Bacteria Inside Tumors Unexpectedly Point to a New Anti-Cancer Pathway

Cancer treatment often views tumors as masses of human cells proliferating out of control. But a tumor is also a complex microenvironment, containing immune cells, blood vessels, stroma, and possibly microbes. A research team at the University of Illinois Chicago has now turned this seemingly unfavorable symbiotic phenomenon into a clue for drug design: certain bacterial proteins found in tumor samples may, in turn, become tools for attacking cancer cells' energy systems.

The focus of this study is a peptide called aurB, inspired by auracyanin B, a copper protein from photosynthetic bacteria. According to UIC Today and a paper published in *Signal Transduction and Targeted Therapy*, researchers identified this class of proteins after analyzing bacterial signals present in human tumor samples and designed a shorter functional fragment, hoping it could enter cancer cells and interfere with the energy supply they need to survive.

Experiments showed that aurB localizes to the mitochondria of cancer cells and inhibits ATP production. ATP is often called the cell's energy currency; for tumor cells that proliferate rapidly and face higher metabolic stress, weakened energy supply may constrain growth and metastatic capacity. The paper further notes that aurB's target involves ATP synthase, distinguishing it from cytotoxic strategies that broadly damage cells and instead focusing on the energy machinery of tumor cells.

The research team tested aurB in prostate cancer cells and animal models, including cell lines with inactivated p53 function and mouse models of prostate cancer resistant to hormone therapy. UIC's account states that aurB can inhibit mitochondrial energy generation in tumor cells and that its effect was most evident when combined with radiation therapy; the journal paper notes that in a tibial bone metastasis model, combination treatment significantly inhibited tumor growth and reduced metastatic lesions in the lungs.

The scientific significance here lies not only in identifying a new peptide, but also in its potential to bypass some limitations of existing anti-cancer strategies. The study authors note that anti-cancer peptides previously derived from the bacterial protein azurin depend more heavily on the p53 pathway, while aurB still showed activity in cancer cells with different p53 states. If subsequent research supports this point, aurB may have greater research value for certain tumors with p53 defects and more difficult treatment options.

However, this remains preclinical research. Tumor suppression in animal models does not equal efficacy in humans, and peptide drugs often face challenges in stability, delivery, dosing, safety, and tumor selectivity. Because aurB targets mitochondrial energy generation, it must also, in theory, be confirmed that its effects on normal tissues with high energy demands are controllable. This is especially important when combined with radiotherapy, where the therapeutic window will need more detailed toxicology data to define it.

UIC says the team has applied for a patent for aurB and is exploring a path toward human clinical trials. This means it has moved one step forward from an observation in tumor microbiology toward a candidate therapeutic concept. But what will truly determine its value is whether subsequent, more rigorous pharmacological, toxicological, and clinical designs can prove that it can not only cut off cancer-cell energy, but also safely and reproducibly bring therapeutic benefit to patients.